Association of IRF4 SNP rs12203592 with melanoma-specific survival

• Authors: SV Ward, The University of Western Australia; DC Gibbs, Emory University; I Orlow, Memorial Sloan Kettering Cancer Center; NE Thomas, University of North Carolina, Chapel Hil; PA Kanetsky, H. Lee Moffitt Cancer Center and Research Institute; L Luo, University of New Mexico; AE Cust, The University of Sydney; H Anton-Culver, University of California, Irvine; SB Gruber, City of Hope National Medical Center; RP Gallagher, University of British Columbia; S Rosso, Piedmont Cancer Registry; R Zanetti, Piedmont Cancer Registry; T Dwyer, University of Oxford; CB Begg, Memorial Sloan Kettering Cancer Center; M Berwick, University of New Mexico
• Journal Title: BRITISH JOURNAL OF DERMATOLOGY
• Volume: Volume 183, Number 1
• Publisher: Wiley | 2020-07-01, Pages 163-165
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1111/bjd.18881
• Subjects: Health Sciences, Epidemiology; Health Sciences, Oncology
• Keywords: IRF4 SNP rs12203592; melanoma-specific survival

Abstract

We have previously shown that the functional melanoma risk variant rs12203592 in interferon regulatory factor-4 (IRF4) was associated with increased Breslow thickness, an important prognostic indicator for melanoma.1 In line with this, a recent study found evidence for an association between the minor T allele of this single nucleotide polymorphism (SNP) and melanoma-specific survival in patients from two European hospitals.